CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash flow from operating activities
Net loss	$ (7,023)	$ (6,750)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization	160	161
Depreciation	251	43
Stock-based compensation	793	784
Change in fair value of warrant liability	(2,374)	(1,713)
Loss on extinguishment of warrant liability	440	0
(Increase) decrease in assets
Prepaid drug product for testing	(741)	184
Other current assets	549	(723)
Increase (decrease) in liabilities
Accounts payable and accrued expenses	0	(146)
Deferred revenue	(12)	12
Net cash used in operating activities	(7,957)	(8,148)
Cash flow from investing activities
Purchases of furniture, fixtures & equipment	(538)	(338)
Net cash used in investing activities	(538)	(338)
Cash flow from financing activities
Net proceeds from sale of common stock	3,567	9,007
Net proceeds from exercise of warrants	1,518	0
Net cash provided by financing activities	5,085	9,007
Net increase (decrease) in cash	(3,410)	521
Cash, beginning of year	9,375	8,854
Cash, end of year	5,965	9,375
Non-cash financing activities
Warrants transferred to equity upon modification	797	0
Conversion of warrant liability to equity	175	0
Capital expenditures included in accrued expense	$ 0	$ 247